Beyond Air, Inc. (XAIR)

NASDAQ: XAIR · IEX Real-Time Price · USD
7.73
+0.29 (3.90%)
At close: Oct 3, 2022 4:00 PM
7.37
-0.36 (-4.66%)
After-hours: Oct 3, 2022 6:00 PM EDT
3.90%
Market Cap 231.03M
Revenue (ttm) n/a
Net Income (ttm) -47.37M
Shares Out 29.89M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 170,952
Open 7.54
Previous Close 7.44
Day's Range 7.30 - 7.90
52-Week Range 4.79 - 16.41
Beta -0.25
Analysts Buy
Price Target 18.97 (+145.4%)
Earnings Date Nov 9, 2022

About XAIR

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteri... [Read more...]

Industry Health Care Equipment & Supplies
CEO Steven Lisi
Employees 62
Stock Exchange NASDAQ
Ticker Symbol XAIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price forecast is 18.97, which is an increase of 145.41% from the latest price.

Price Target
$18.97
(145.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of Hig...

GARDEN CITY, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of ...

16 hours ago - GlobeNewsWire

Beyond Air® To Participate in Three Upcoming Investor Conferences

GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of...

2 weeks ago - GlobeNewsWire

Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentratio...

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nit...

1 month ago - GlobeNewsWire

Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time Call scheduled for Thursday, August 11th at 4:30 pm Eastern Time

2 months ago - GlobeNewsWire

Beyond Air (XAIR) Stock Gains Almost 20% on FDA Approval

XAIR stock is jumping nearly 20% and is trending on many social media websites. The company's LungFit PH device was approved by the FDA.

3 months ago - InvestorPlace

Beyond Air Scores First FDA Approval For LungFit PH In Respiratory Failure

The FDA has approved Beyond Air Inc's (NASDAQ: XAIR) LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newbo...

3 months ago - Benzinga

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun

3 months ago - GlobeNewsWire

Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide  unlimited, on-dema...

3 months ago - GlobeNewsWire

Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) fo...

3 months ago - GlobeNewsWire

Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer.

4 months ago - GlobeNewsWire

Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

Ms. Jones brings over 30 years of life science based financial experience to Beyond Cancer Ms. Jones brings over 30 years of life science based financial experience to Beyond Cancer

4 months ago - GlobeNewsWire

Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

Call scheduled for Thursday, June 16th at 4:30 pm Eastern Time Call scheduled for Thursday, June 16th at 4:30 pm Eastern Time

4 months ago - GlobeNewsWire

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at th...

GARDEN CITY, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...

5 months ago - GlobeNewsWire

Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022

Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard s...

5 months ago - GlobeNewsWire

Beyond Air® to Participate in Three Upcoming Medical Conferences

GARDEN CITY, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for t...

5 months ago - GlobeNewsWire

Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ul...

Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune r...

5 months ago - GlobeNewsWire

Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Mee...

Abstracts for the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM ET Abstracts for the American Association for Cancer Research (AACR) Annual Meeti...

6 months ago - GlobeNewsWire

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark

7 months ago - GlobeNewsWire

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

7 months ago - GlobeNewsWire

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships

8 months ago - GlobeNewsWire

New Strong Sell Stocks for January 27th

ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022

Other symbols: ARAYEMKR
8 months ago - Zacks Investment Research

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time Call scheduled for Thursday, February 10th at 4:30 pm Eastern Time

8 months ago - GlobeNewsWire

Implied Volatility Surging for Beyond Air (XAIR) Stock Options

Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Beyond Air Shares Fall As US Launch Of LungFit PH Not Expected In 2021

Beyond Air Inc (NASDAQ: XAIR) expects a delay in FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn. Based on ongoing communications with the FDA, the company no longer bel...

9 months ago - Benzinga

Why Beyond Air Stock Is Tanking Today

A regulatory delay is weighing heavily on the medical device company's shares today.

9 months ago - The Motley Fool